Thomas Sbarrato
33 works · 1,129 citations · h-index 12
Top works
- Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trial
- The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape
- RTN3 Is a Novel Cold-Induced Protein and Mediates Neuroprotective Effects of RBM3
- Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer
- A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma
- Immunoscore immune checkpoint using spatial quantitative analysis of CD8 and PD-L1 markers is predictive of the efficacy of anti- PD1/PD-L1 immunotherapy in non-small cell lung cancer
- Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer
- Inhibition of Sec61-dependent translocation by mycolactone uncouples the integrated stress response from ER stress, driving cytotoxicity via translational activation of ATF4
- Suboptimal T-cell receptor signaling compromises protein translation, ribosome biogenesis, and proliferation of mouse CD8 T cells
- An improved analysis methodology for translational profiling by microarray
- A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment
- TAp73 contributes to the oxidative stress response by regulating protein synthesis
- A Bistable Mechanism Mediated by Integrins Controls Mechanotaxis of Leukocytes
- Ribosomes and Stress – Linked from Birth to Death
- Upfront FOLFOXIRI Plus Bevacizumab with or Without Atezolizumab in the Treatment of Patients with Metastatic Colorectal Cancer (ATEZOTRIBE): A Multicentre, Open-Label, Phase 2, Randomised Controlled Trial by GONO
- EIF4B (eukaryotic translation initiation factor 4B)
- Correction: Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
- Efficacy of anti-PD1/PD-L1 immunotherapy in non–small cell lung cancer is dependent upon Immunoscore IC CD8 and PD-L1 status.
- Risk stratification using the Decipher 22-gene genomic classifier (GC) and digital pathology artificial intelligence (DPAI) in nearly 10,000 localized prostate cancer patients.
- Abstract 870: Immunoscore® workflow enhanced by artificial intelligence